Skip To Content

Study ID: Vertex VX16-659-101


A Phase II, Randomized, Double blind, controlled study to evaluate the safety and efficacy of of 659 Combination Therapy in Subjects Aged 18 years and Older with Cystic Fibrosis

Title:A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis Description: Vertex Pharmaceuticals Incorporated, is developing an investigational drug called VX-659 to treat people living with CF. This study is being done to learn more about the safety and effects of various strengths and combinations of VX-659, ivacaftor (IVA) and/or tezacaftor (TEZ) in people living with CF.
Sioux Falls Region
Principal Investigator:
James Wallace, MD
Phase II
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.